Aptar, Inc. reported its financial results for the first quarter of 2021, which was resilient despite the ongoing COVID-19 pandemic. The company's food and beverage segment delivered a stellar performance, driven by increased demand for innovative food dispensing closures. The pharma segment also performed well, with increased demand for injectable components and active material science solutions, including those for COVID-19 test kits. The beauty and home segment experienced a decline in sales to the beauty market due to continued low levels of retail beauty activity related to the pandemic, but core sales to the personal care and home care markets increased. Aptar's adjusted EBITDA margin was comparable to the prior year, despite a mix shift within the pharma segment and the relative mix across its three segments. The company's balance sheet remained strong, with a leverage ratio of 1.4 and a net cash position of approximately 31%. Aptar continues to invest in innovative growth projects and is confirming its forecasted range of capital expenditures for the year at a range of $300 million to $330 million. The company's commitment to